C
0.990
0.04 (4.21%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Clearside Biomedical, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
1.0
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.00 |
|
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 7.76% |
| 机构持股比例 | 20.11% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Carmignac Gestion | 31 Dec 2024 | 1,933,531 |
| Brown Wealth Management, Llc | 31 Dec 2024 | 100,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 6.00 (HC Wainwright & Co., 506.06%) | 购买 |
| 6.00 (Chardan Capital, 506.06%) | 购买 | |
| 中 | 5.50 (455.56%) | |
| 低 | 4.00 (Needham, 304.04%) | 购买 |
| 平均值 | 5.25 (430.30%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 0.960 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 31 Mar 2025 | 6.00 (506.06%) | 购买 | 0.990 |
| 06 Mar 2025 | 6.00 (506.06%) | 购买 | 0.976 | |
| Chardan Capital | 28 Mar 2025 | 6.00 (506.06%) | 购买 | 0.950 |
| Citizens Capital Markets | 28 Mar 2025 | 5.00 (405.05%) | 购买 | 0.950 |
| Needham | 28 Mar 2025 | 4.00 (304.04%) | 购买 | 0.950 |
| 06 Mar 2025 | 6.00 (506.06%) | 购买 | 0.976 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合